The impact of structural optical coherence tomography changes on visual function in retinal vein occlusion.
Aged
Angiogenesis Inhibitors
/ administration & dosage
Cross-Sectional Studies
Female
Humans
Intravitreal Injections
Male
Prospective Studies
Ranibizumab
/ administration & dosage
Retinal Vein Occlusion
/ diagnosis
Retinal Vessels
/ diagnostic imaging
Tomography, Optical Coherence
/ methods
Vascular Endothelial Growth Factor A
/ antagonists & inhibitors
Visual Acuity
/ physiology
biomarker
function
morphology
optical coherence tomography
retinal vein occlusion
Journal
Acta ophthalmologica
ISSN: 1755-3768
Titre abrégé: Acta Ophthalmol
Pays: England
ID NLM: 101468102
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
19
11
2019
accepted:
18
08
2020
pubmed:
1
10
2020
medline:
25
11
2021
entrez:
30
9
2020
Statut:
ppublish
Résumé
We aimed to determine the correlation between optical coherence tomography (OCT)- and demographic features and baseline best corrected visual acuity (BCVA) in treatment-naïve patients with retinal vein occlusion (RVO). This was a cross-sectional posthoc analysis of OCT images that included RVO patients from two prospective, open-label, multicentre studies. The morphological grading was done manually, in the standardized setting of a reading centre. Main outcome measure was the estimated difference in Early Treatment Diabetic Retinopathy Study letters associated with each individual biomarker. Included were 381/301 treatment-naïve patients with BRVO/CRVO. For BRVO, statistically significant correlations with BCVA were seen for a 100 µm increase in central subfield thickness (CST; -3.1 letters), intraretinal cysts at centre point (CP; +4.1), subretinal fluid (SRF) at CP (+3.0) and hyperreflective foci (HRF) at the central B-scan (-2.2). In CRVO, a 100 µm increase in CST was associated with a loss of -3.4 letters. In the total cohort, 100 µm increase in CST, SRF at CP and HRF at the central B-scan correlated with a difference of -3.2,+3.2 and -2.0 letters. A 10-year increase in age and female gender yielded a -2.0 and -2.5 letter decrease in the total cohort. Adjusted multiple R Of all parameters studied, only CST and age were consistently associated with worse BCVA in treatment-naïve RVO patients. Morphology on OCT explained only a modest part of functional loss in this patient cohort.
Identifiants
pubmed: 32996711
doi: 10.1111/aos.14621
pmc: PMC8359321
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Vascular Endothelial Growth Factor A
0
Ranibizumab
ZL1R02VT79
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
418-426Informations de copyright
© 2020 The Authors. Acta Ophthalmologica published by John Wiley & Sons Ltd on behalf of Acta Ophthalmologica Scandinavica Foundation.
Références
Arch Ophthalmol. 1999 Jun;117(6):821-3
pubmed: 10369597
Int J Ophthalmol. 2017 Feb 18;10(2):271-276
pubmed: 28251088
Invest Ophthalmol Vis Sci. 2009 Mar;50(3):1025-32
pubmed: 19060280
Br J Ophthalmol. 2007 Dec;91(12):1644-9
pubmed: 17504858
Am J Ophthalmol. 2014 Aug;158(2):372-380.e1
pubmed: 24794089
Invest Ophthalmol Vis Sci. 2017 Aug 1;58(10):4039-4048
pubmed: 28813577
JAMA Ophthalmol. 2019 Jan 1;137(1):46-47
pubmed: 30286233
Sci Rep. 2018 Jun 25;8(1):9626
pubmed: 29942024
Ophthalmology. 2012 May;119(5):1024-32
pubmed: 22440275
Ophthalmology. 2013 Sep;120(9):1860-70
pubmed: 23642377
Retina. 2016 Dec;36(12):2319-2328
pubmed: 27258668
Ophthalmology. 2015 Apr;122(4):822-32
pubmed: 25578255
Am J Ophthalmol. 2010 Feb;149(2):291-301.e5
pubmed: 20103055
Ophthalmology. 2012 Jun;119(6):1190-8
pubmed: 22361318
Ophthalmology. 2011 Oct;118(10):2041-9
pubmed: 21715011
Graefes Arch Clin Exp Ophthalmol. 2010 Feb;248(2):155-9
pubmed: 19763601
Graefes Arch Clin Exp Ophthalmol. 2010 Nov;248(11):1567-72
pubmed: 20596719
Retina. 2014 Jun;34(6):1132-41
pubmed: 24378425
Ophthalmology. 2014 Jul;121(7):1414-1420.e1
pubmed: 24679444
Br J Ophthalmol. 2014 Dec;98(12):1629-35
pubmed: 25079064
Ophthalmology. 2008 Feb;115(2):355-362.e2
pubmed: 17675242
Acta Ophthalmol. 2011 Feb;89(1):e35-40
pubmed: 21155986
Invest Ophthalmol Vis Sci. 2011 May 18;52(6):3334-7
pubmed: 21087958
Clin Ophthalmol. 2016 Jul 18;10:1305-13
pubmed: 27486302
N Engl J Med. 2010 Nov 25;363(22):2135-44
pubmed: 21105795
Exp Ther Med. 2018 Jan;15(1):890-896
pubmed: 29399095
Nat Biomed Eng. 2018 Mar;2(3):158-164
pubmed: 31015713
Ophthalmology. 2011 Aug;118(8):1594-602
pubmed: 21684606
IEEE Trans Med Imaging. 2017 Sep;36(9):1773-1783
pubmed: 28475051
Ophthalmology. 2018 Apr;125(4):549-558
pubmed: 29224926
Ophthalmology. 2009 Mar;116(3):504-12
pubmed: 19167078
Ophthalmology. 2017 Dec;124(12):1778-1787
pubmed: 28807635
Ophthalmology. 2011 Feb;118(2):345-52
pubmed: 20926135
Int J Ophthalmol. 2018 Feb 18;11(2):256-261
pubmed: 29487816
Graefes Arch Clin Exp Ophthalmol. 2013 Feb;251(2):501-8
pubmed: 22653439
Eur J Ophthalmol. 2012 Nov-Dec;22(6):1013-8
pubmed: 22569812
Int J Ophthalmol. 2017 Apr 18;10(4):605-612
pubmed: 28503435
Ophthalmology. 2016 Jun;123(6):1332-44
pubmed: 27039022
J Ophthalmol. 2013;2013:974670
pubmed: 24490054
Ophthalmology. 2016 May;123(5):1101-11
pubmed: 26896124
JAMA Ophthalmol. 2014 Nov;132(11):1309-16
pubmed: 25058813
Graefes Arch Clin Exp Ophthalmol. 2009 Dec;247(12):1635-41
pubmed: 19633982
Graefes Arch Clin Exp Ophthalmol. 2014 Sep;252(9):1413-21
pubmed: 24577742
J Ophthalmic Vis Res. 2018 Jul-Sep;13(3):315-332
pubmed: 30090189
Am J Ophthalmol. 2014 Nov;158(5):1032-8
pubmed: 25068637
Ophthalmology. 2016 Jan;123(1):60-9
pubmed: 26481821
Retina. 2018 Mar;38(3):559-568
pubmed: 28248827
Ophthalmology. 2009 Nov;116(11):2158-64
pubmed: 19700195
Clin Exp Ophthalmol. 2009 Mar;37(2):208-16
pubmed: 19426405
Int J Ophthalmol. 2016 Jan 18;9(1):86-92
pubmed: 26949616